Search

Inter-individual variability in Pharmacokinetic (PK) and Pharmacodynamic (PD) models significantly affects the accuracy of Target Controlled Infusion and closed-loop control of anesthesia. We hypothesize that the novel Eleveld PK model captures more inter-individual variability relevant to both open-loop and closed-loop control design, resulting in reduced variability in PD models identified using the Eleveld PK model's plasma prediction compared to the Schuttler or Schnider PK model. We used a dataset of propofol infusion rates and Depth of Hypnosis measurements across three demographic groups: elderly, obese, and adult. PD models are identified based on plasma concentration prediction using three PK models (Schuttler, Schnider, and Eleveld). Validation methods are presented to confirm acceptable predictive performance and comparable PK-PD model variability within each demographic group. To test our hypothesis, we compared coefficient variations in step responses for open-loop control and multiplicative uncertainty of PD model sets for closed-loop control. Validated PKPD models using the Schuttler and Schnider PK model showed no significant differences in predictive response and multiplicative uncertainty compared to the Eleveld PK model. The coefficient variations in step responses of PD model sets and the frequency ranges, corresponding to uncertainty below one, were comparable for all three PK models. The comparison of the accumulated coefficient of variation in the step-response and the uncertainty of the PD model sets indicated that the Eleveld PK model does not offer any advantage for the design of open-loop or closed-loop control of anesthesia., (© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)

Background and Objective: New proposals to improve the regulation of hypnosis in anaesthesia based on the development of advanced control structures emerge continuously. However, a fair study to analyse the real benefits of these structures compared to simpler clinically validated PID-based solutions has not been presented so far. The main objective of this work is to analyse the performance limitations associated with using a filtered PID controller, as compared to a high-order controller, represented through a Youla parameter., Methods: The comparison consists of a two-steps methodology. First, two robust optimal filtered PID controllers, considering the effect of the inter-patient variability, are synthesised. A set of 47 validated paediatric pharmacological models, identified from clinical data, is used to this end. This model set provides representative inter-patient variability Second, individualised filtered PID and Youla controllers are synthesised for each model in the set. For fairness of comparison, the same performance objective is optimised for all designs, and the same robustness constraints are considered. Controller synthesis is performed utilising convex optimisation and gradient-based methods relying on algebraic differentiation. The worst-case performance over the patient model set is used for the comparison., Results: Two robust filtered PID controllers for the entire model set, as well as individual-specific PID and Youla controllers, were optimised. All considered designs resulted in similar frequency response characteristics. The performance improvement associated with the Youla controllers was not significant compared to the individually tuned filtered PID controllers. The difference in performance between controllers synthesized for the model set and for individual models was significantly larger than the performance difference between the individual-specific PID and Youla controllers. The different controllers were evaluated in simulation. Although all of them showed clinically acceptable results, the robust solutions provided slower responses., Conclusion: Taking the same clinical and technical considerations into account for the optimisation of the different controllers, the design of individual-specific solutions resulted in only marginal differences in performance when comparing an optimal Youla parameter and its optimal filtered PID counterpart. The inter-patient variability is much more detrimental to performance than the limitations imposed by the simple structure of the filtered PID controller., (Copyright © 2020 Elsevier B.V. All rights reserved.)

Closed-loop controlled drug dosing has the potential of revolutionizing clinical anesthesia. However, inter-patient variability in drug sensitivity poses a central challenge to the synthesis of safe controllers. Identifying a full individual pharmacokinetic-pharmacodynamic (PKPD) model for this synthesis is clinically infeasible due to limited excitation of PKPD dynamics and presence of unmodeled disturbances. This work presents a novel method to mitigate inter-patient variability. It is based on: 1) partitioning an a priori known model set into subsets; 2) synthesizing an optimal robust controller for each subset; 3) classifying patients into one of the subsets online based on demographic or induction phase data; 4) applying the associated closed-loop controller. The method is investigated in a simulation study, utilizing a set of 47 clinically obtained patient models. Results are presented and discussed.Clinical relevance-The proposed method is easy to implement in clinical practice, and has potential to reduce the impact from surgical stimulation disturbances, and to result in safer closed-loop anesthesia with less risk of under- and over dosing.

In safety-critical control systems, such as closed-loop control of anesthesia, it is of utmost importance to guarantee the ability of a control approach to maintain states of the systems within a safe region. In this paper, we address the problem by applying a safety-preserving control technique to anesthesia control. The approach relies on a conservative approximation of the viability set. The set specifies initial states for which there exists an input that keeps the trajectory emanating from those states within the safe region. This approach can be applied to any type of controller which satisfies the performance criteria. Furthermore, it prevents the performance controller from taking the states out of the safe region.

Closed-loop control of anesthesia is expected to decrease drug dosage and wake up time while increasing patient safety and decreasing the work load of the anesthesiologist. The potential of closed-loop control in anesthesia has been demonstrated in several clinical studies. One of the challenges in the development of a closed-loop system that can be widely accepted by clinicians and regulatory authorities is the effect of interpatient variability in drug sensitivity. This system uncertainty may lead to unacceptable performance, or even instability of the closed-loop system for some individuals. The development of reliable models of the effect of anesthetic drugs and characterization of the uncertainty is, therefore, an important step in the development of a closed-loop system. Model identification from clinical data is challenging due to limited excitation and the lack of validation data. In this paper, approximate models are validated for controller design by evaluating the predictive accuracy of the closed-loop behavior. A set of 47 validated models that describe the interpatient variability in the response to propofol in children is presented. This model set can be used for robust linear controller design provided that the experimental conditions are similar to the conditions during data collection.

Dose-dependent effects of ketamine on processed electroencephalographic depth-of-hypnosis indices have been reported. Limited data are available for the NeuroSENSE WAVCNS index. Our aim was to establish the feasibility of closed-loop propofol-remifentanil anesthesia guided by the WAVCNS index in the presence of an analgesic dose of ketamine. Thirty ASA I-II adults, 18-54 years, requiring general anesthesia for anterior cruciate ligament surgery were randomized to receive: full-dose [ketamine, 0.5 mg kg-1 initial bolus, 10 mcg kg-1 min-1 infusion] (recommended dose for postoperative pain management); half-dose [ketamine, 0.25 mg kg-1 bolus, 5 mcg kg-1 min-1 infusion]; or control [no ketamine]. After the ketamine bolus, patients received 1.0 mcg kg-1 remifentanil over 30 s, then 1.5 mg kg-1 propofol over 30 s, followed by manually-adjusted propofol-remifentanil anesthesia. The WAVCNS was > 60 for 7/9 patients in the full-dose group at 7 min after starting the propofol infusion. This was inconsistent with clinical observations of depth-of-hypnosis and significantly higher than control (median difference [MD] 17.0, 95% confidence interval [CI] 11.4-26.8). WAVCNS was median [interquartile range] 49.3 [42.2-62.6] in the half-dose group, and not different to control (MD 5.1, 95% CI - 4.9 to 17.9). During maintenance of anesthesia, the WAVCNS was higher in the full-dose group compared to control (MD 14.7, 95% CI 10.2-19.2) and in the half-dose group compared to control (MD 11.4, 95% CI 4.7-20.4). The full-dose of ketamine recommended for postoperative pain management had a significant effect on the WAVCNS. This effect should be considered when using the WAVCNS to guide propofol-remifentanil dosing.Trial Registration ClinicalTrails.gov No. NCT02908945. [ABSTRACT FROM AUTHOR]

This brief introduces a novel safety-preserving control scheme with minimal conservatism for uncertain systems. We have recently introduced the model-invariant safety verification technique that provides a formal guarantee of safety for systems with multiplicative model uncertainty. This approach requires a multi-model description of model uncertainty. The resulting safety system may be conservative for systems that do not exhibit the worst case dynamical response. In this brief, we employ model falsification to reduce conservatism of the model-invariant safety verification technique. Members of a model set that characterizes model uncertainty are falsified if discrepancy between predictions of those models and measured responses of the uncertain system is established, thereby reducing model uncertainty. To demonstrate the effectiveness of the proposed technique, we formalize a model-invariant safety system for closed-loop propofol anesthesia. The safety system maintains predicted propofol concentration in plasma as well as the patient’s blood pressure within safety bounds despite uncertainty in patient responses to propofol. [ABSTRACT FROM AUTHOR]

Feasibility of closed-loop propofol anesthesia has been demonstrated in clinical trials; however, no closed-loop system is currently routinely used in clinical practice. Data from closed-loop clinical trials provide valuable information for system evaluation prior to market approval, including outlier behavior. To exploit this valuable data, closed-loop identification in the presence of nonzero disturbances is required. Disturbances due to stimulation are not zero mean and will cause bias in models identified from clinical data. In this paper, we use multiple-input single-output (MISO) closed-loop identification to take the response to disturbances during induction of anesthesia into account. It is shown that direct MISO output-error identification introduces limited bias for this specific closed-loop identification problem and the use of more complex closed-loop identification methods does not improve model accuracy. Using this approach, we identify and validate a set of models that describes both the blood pressure and the depth-of-hypnosis response to propofol infusion for patients at risk of cardiovascular suppression. Quantification of both these responses for the same patients provides a valuable basis for the design and evaluation of constrained control systems. [ABSTRACT FROM AUTHOR]

Objective: The goal of this paper was to optimize robust PID control for propofol anesthesia in children aged 5–10 years to improve performance, particularly to decrease the time of induction of anesthesia while maintaining robustness. Methods: We analyzed results of a previous study conducted by our group to identify opportunities for system improvement. Allometric scaling was introduced to reduce the interpatient variability and a new robust PID controller was designed using an optimization-based method. We evaluated this optimized design in a clinical study involving 16 new cases. Results: The optimized controller design achieved the performance predicted in simulation studies in the design stage. Time of induction of anesthesia was median [Q1, Q3] 3.7 [2.3, 4.1] min and the achieved global score was 13.4 [9.9, 16.8]. Conclusion: Allometric scaling reduces the interpatient variability in this age group and allows for improved closed-loop performance. The uncertainty described by the model set, the predicted closed-loop responses, and the predicted robustness margins are realistic. The system meets the design objectives of improved speed of induction of anesthesia while maintaining robustness and improving clinically relevant system behavior. Significance: Control system optimization and ongoing system improvements are essential to the development of a clinically relevant commercial device. This paper demonstrates the validity of our approach, including system modeling, controller optimization, and pre-clinical testing in simulation. [ABSTRACT FROM AUTHOR]

This paper describes the design and evaluation of a controller for multi-input single-output (MISO) propofol-remifentanil anesthesia, guided by feedback from a measure of depth-of-hypnosis (DOH). DOH monitors are commonly used in clinical practice to guide anesthetic dosing, however, there is currently no widely accepted nociception monitor to guide remifentanil (analgesic) infusion. Variability in the DOH measure has been associated with insufficient analgesia, and feasibility of closed-loop control of both propofol and remifentanil infusion using DOH feedback has been demonstrated. However, DOH variability does not provide a measure of analgesia in the absence of stimulation. Consequently, control of the opioid-hypnotic balance is lost in control systems relying on DOH feedback alone. The proposed design overcomes this limitation by introducing a second, indirect control objective. This paper defines clinical design specifications to achieve adequate anesthesia in a wide range of clinical cases, proposes a modification of the habituating control framework, and presents methods to translate the clinical objectives into control objectives within this framework. The developed design methodology provides a controller that: 1) meets the clinical objectives; 2) is robust to interpatient variability, both in single-input single-output and MISO operation; 3) is robust to nonlinear drug interactions; 4) gives the user control of the opioid-hypnotic balance in the absence of stimulation and in the presence of input saturation; and 5) improves disturbance rejection following nociceptive stimulation. The MISO system performed as designed in 80 clinical cases. [ABSTRACT FROM AUTHOR]

This paper describes the design of a robust proportional-integral derivative (PID) controller for propofol infusion in children and presents the results of clinical evaluation of this closed-loop system during endoscopic investigations in children age 6–17. The controller design is based on a set of models that describes the interpatient variability in the response to propofol infusion in the study population. The PID controller is tuned to achieve sufficient robustness margins for the identified uncertainty. 108 children were enrolled in this study, and anesthesia was closed-loop controlled in 102 of these cases. Clinical evaluation of the system shows that closed-loop control of both induction and maintenance of anesthesia in children based on the WAVCNS index as a measure of clinical effect is feasible. A robustly tuned PID controller can accommodate the interpatient variability in children and spontaneous breathing can be maintained in most subjects. [ABSTRACT FROM AUTHOR]

This paper studies application of different constrained control concepts for the control of Depth of Hypnosis (DOH) in closed-loop anesthesia to guarantee patient safety, while ensuring acceptable tracking performance. The core idea is to formulate Overdosing (OD) prevention and Blood Pressure Decrease (BPD) prevention as operational constraints, and then use a constrained control scheme to enforce the constraints satisfaction at all times. In this paper, three methods are studied: (1) Explicit Reference Governor (ERG), (2) Safety Preserving Control (SPC), and (3) Model Predictive Control (MPC). The performance of the methods is assessed with respect to a simulated surgical procedure for 44 patients whose models have been identified using clinical data. In particular, three realistic clinical scenarios are studied in this paper: (1) normal mode, (2) stimulation, and (3) low clearance. The results demonstrate cons and pros of each method in closed-loop anesthesia according to clinically relevant assessments. [ABSTRACT FROM AUTHOR]

• Habituating MPC provides a unique control solution for MISO systems. • Extended HMPC provides a clinically relevant MPC control objective function. • Simulation results show that the extended design meets clinical objectives. • This solution can facilitate practical implementation of patient safety constraints. This paper proposes a model predictive control (MPC) solution for closed-loop propofol and remifentanil infusion based on feedback from a depth-of-hypnosis monitor, a multi-input single-output system. A clinically relevant objective function is proposed, extending the habituating MPC solution. The presented MPC controller meets the following clinical objectives; it (1) gives the anesthesiologist control over the analgesic-hypnotic balance, (2) reacts fast in response to disturbances, (3) maintains a bounded response to noise, and (4) is robustly stable toward patient variability. The proposed MPC framework and controller design will facilitate practical implementation of patient safety constraints compared to previously proposed LTI solutions. [ABSTRACT FROM AUTHOR]